彭布罗利珠单抗
医学
安慰剂
依托泊苷
内科学
期限(时间)
肿瘤科
化疗
免疫疗法
病理
癌症
天文
替代医学
物理
作者
C.M. Rudin,H.R. Kim,A. Navarro,M. Gottfried,Yi-Long Wu,Tibor Csőszi,P.K. Cheema,Delvys Rodriguez-Abreu,Mira Wollner,G. Czyżewicz,Jun Yang,J. Mazieres,F.J. Orlandi,Alexander Luft,M. Gümüş,T. Kato,G.P. Kalemkerian,W. Fu,B. Zhao,Hazem E El-Osta,M.M. Awad
标识
DOI:10.1016/j.jtho.2022.07.063
摘要
In the phase 3 KEYNOTE-604 study of pembrolizumab + etoposide/platinum (EP) versus placebo + EP as first-line therapy for ES-SCLC (NCT03066778), PFS was significantly improved with pembrolizumab + EP versus placebo + EP (HR, 0.75 [95% CI, 0.61-0.91]; P=0.0023) and although the HR for OS favored pembrolizumab + EP, the significance threshold was not met (HR, 0.80 [95% CI, 0.64-0.98]; P=0.0164). We present updated results with ∼3.5 years of follow-up and outcomes in patients who completed 35 cycles of pembrolizumab.
科研通智能强力驱动
Strongly Powered by AbleSci AI